Treatment of moderate and severe bacterial infection with biapenem in patients with underlying disease

Objective To evaluate the efficacy and safety of biapenem in the treatment of moderate and severe bacterial infection in patients with underlying diseases. Methods Total of 44 patients with moderate and severe bacterial infection of underlying diseases, were randomly divided into the control group(piperacillin/tazobactam group) with 24 cases and the treatment groups(biapenem group) with 20 cases, control group were treated with piperacillin/tazobactam 2.25-4.5 g for 3 times a day intravenously, 0.3 g biapenem was used for treatment group intravenously 3 times a day, the course of treatment was generally 10 days, the efficacy and adverse reactions were observed of two groups, respectively. Results The efficacious rates of biapenem and piperacillin/tazobactam were 75.0%(15/20) and 70.8%(17/24), respectively. The bacterial clearance rate was 70.0%(14/20) in biapenem treatment group and 66.7%(16/24) in piperacillin/ tazobactam treatment group with no significant difference. The clinical efficacy of biapenem was 75.0% treatment, while the adverse reaction rate was 10.0%. Conclusion Biapenem is effective and safe for treatment of moderate and severe bacterial infection in patients with underlying diseases.